MEDX Oncology West


Session 11: Evidence-based Updates in Non-Hodgkin’s Lymphoma

Saturday, November 18     3:20pm – 4:40pm

Description

Significant advances in treatment with novel agents for B-cell non-Hodgkin’s lymphoma (NHL) have improved patient outcomes and survival. However, many patients are at high-risk of relapse, meriting a precision approach to reduce the rate of recurrence and improve outcomes. The identification of molecular subtypes, the persistence of clinical challenges, and the anticipated emergence of clinical data necessitate a collaborative treatment approach to ensure individualized care for patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Session Outline

Faculty will discuss 3 patient stories to highlight the factors that impact treatment decisions in DLBCL, MCL, and FL. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • The evolving role of genomics
  • Clinical guidelines and current treatment options
  • Risk-adapted treatment strategies: High-risk, elderly, aggressive
  • Maintenance therapy after relapsed/refractory treatment
  • Emerging efficacy and safety data from clinical trials of novel agents and combinations in the relapsed/refractory setting

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 1.25 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 hours (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon